Advertisement
Canada markets close in 5 hours 57 minutes

  • S&P/TSX

    21,951.42
    +66.04 (+0.30%)
     

  • S&P 500

    5,097.25
    +48.83 (+0.97%)
     

  • DOW

    38,275.43
    +189.63 (+0.50%)
     

  • CAD/USD

    0.7319
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    83.95
    +0.38 (+0.45%)
     

  • Bitcoin CAD

    88,067.84
    +1,577.92 (+1.82%)
     

  • CMC Crypto 200

    1,334.71
    -61.82 (-4.43%)
     

  • GOLD FUTURES

    2,351.60
    +9.10 (+0.39%)
     

  • RUSSELL 2000

    1,995.53
    +14.41 (+0.73%)
     

  • 10-Yr Bond

    4.6550
    -0.0510 (-1.08%)
     

  • NASDAQ

    15,880.23
    +268.47 (+1.72%)
     

  • VOLATILITY

    15.34
    -0.03 (-0.20%)
     

  • FTSE

    8,129.75
    +50.89 (+0.63%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6833
    +0.0012 (+0.18%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Results from 'Magnificent Seven' duo show cloud revenue boosted by strong AI demand

Pfizer Has Another Blockbuster on the Horizon, but That's Not All

Prosper Junior Bakiny, The Motley Fool
·4 min read
Pfizer Has Another Blockbuster on the Horizon, but That's Not All

Over the past year, Pfizer (NYSE: PFE) made a series of acquisitions, even announcing at one point that it planned to remain "very active in deal-making." On March 13, Pfizer announced the planned blockbuster acquisition of cancer specialist Seagen (NASDAQ: SGEN) for a massive $43 billion in cash. This move, expected to close by year-end or early 2024, will likely improve Pfizer's prospects, and it is only the latest in a series of important and successful strategic decisions the company's management has made.

Continue reading